Cardiac fibrosis
Open accessThe DOI matches its Crossref record; 612 of the 615 references it cites were found in a registry or an index.
Abstract
Myocardial fibrosis, the expansion of the cardiac interstitium through deposition of extracellular matrix proteins, is a common pathophysiologic companion of many different myocardial conditions. Fibrosis may reflect activation of reparative or maladaptive processes. Activated fibroblasts and myofibroblasts are the central cellular effectors in cardiac fibrosis, serving as the main source of matrix proteins. Immune cells, vascular cells and cardiomyocytes may also acquire a fibrogenic phenotype under conditions of stress, activating fibroblast populations. Fibrogenic growth factors (such as transforming growth factor-β and platelet-derived growth factors), cytokines [including tumour necrosis factor-α, interleukin (IL)-1, IL-6, IL-10, and IL-4], and neurohumoral pathways trigger fibrogenic signalling cascades through binding to surface receptors, and activation of downstream signalling cascades. In addition, matricellular macromolecules are deposited in the remodelling myocardium and regulate matrix assembly, while modulating signal transduction cascades and protease or growth factor activity. Cardiac fibroblasts can also sense mechanical stress through mechanosensitive receptors, ion channels and integrins, activating intracellular fibrogenic cascades that contribute to fibrosis in response to pressure overload. Although subpopulations of fibroblast-like cells may exert important protective actions in both reparative and interstitial/perivascular fibrosis, ultimately fibrotic changes perturb systolic and diastolic function, and may play an important role in the pathogenesis of arrhythmias. This review article discusses the molecular mechanisms involved in the pathogenesis of cardiac fibrosis in various myocardial diseases, including myocardial infarction, heart failure with reduced or preserved ejection fraction, genetic cardiomyopathies, and diabetic heart disease. Development of fibrosis-targeting therapies for patients with myocardial diseases will require not only understanding of the functional pluralism of cardiac fibroblasts and dissection of the molecular basis for fibrotic remodelling, but also appreciation of the pathophysiologic heterogeneity of fibrosis-associated myocardial disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction1,2.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [2]
In the citing paper
“Among stromal cell types, fibroblasts are of particular interest given their role in tissue fibrosis, arrhythmias, and heart failure 16,29,30 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [30]
Citations
Cites
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495 · cited 1×
“Fibrosis is an important cause of organ dysfunction in many different diseases, including interstitial lung diseases, liver cirrhosis, progressive systemic sclerosis, and diabetic nephropathy.(1)”
BackgroundMyofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Obesity and the risk of heart failure
Kenchaiah, S., Evans, J. C., Levy, D., Wilson, P. W. F., Benjamin, E. J., Larson, M. G., Kannel, W. B., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020245 · Cited by 3,093
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
Self-citationEndothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222 · cited 2×
“The antifibrotic effects were attributed to blockade of TGF-b signalling and were associated with attenuated endothelial to mesenchymal transition.(22,247) Moreover, gain-of-function studies have”
BackgroundHinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, G. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070112 · Cited by 2,068
Cited by
Items 201–300 of 1,000
IL ‐6 in the spotlight: From cardiovascular pathophysiology to therapy
Preda, A., Tirandi, A., Leo, G., Vece, D. D., Vilahur, G., Bonaventura, A., Osto, E., Ministrini, S., Kraler, S. C., Kleinbogard, P., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70161 · Cited by 31
“106,107 IL-6 promotes fibrosis via MAPK-and CAMKII-STAT3–dependent pathways and acts downstream of hypoxia-induced mitogenic factor, with its inhibition preventing fibroblast activation.”
Teer, E., Dominick, L., Mukonowenzou, N. C., & Essop, M. F. (2022) · Cells · doi:10.3390/cells11182825 · Cited by 32
“Furthermore, the activation of myofibroblasts require the co-operation of growth factors and specialized matrix proteins, which signal through cell surface receptors to activate intracellular signaling pathways that can lead to the synthesis of contractile proteins and the transcription of matrix macromolecules [68].”
BackgroundLncRNA MEG3: Potential stock for precision treatment of cardiovascular diseases
Li, Z., Gao, J., Sun, D., Jiao, Q., Ma, J., Cui, W., Lou, Y., Xu, F., Li, S., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1045501 · Cited by 32
“Upon injury, CFs are activated into myofibroblasts that produce matrix metalloproteinases (MMPs) (Eghbali et al., 1989; Spinale, 2007; Travers et al., 2016; Frangogiannis, 2021).”
BackgroundJeong, A., Lim, Y., Kook, T., Kwon, D., Cho, Y. K., Ryu, J., Lee, Y.-G., Shin, S., Choe, N., Kim, Y. S., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102071 · Cited by 30
Uhlig, M., Billig, S., Wienhold, J., & Schumacher, D. (2025) · Cells · doi:10.3390/cells14050345 · Cited by 29
“Re-placement fibrosis occurs after irreversible injury, such as myocardial infarction, in which necrotic cardiomyocytes are replaced by a dense, collagen-rich scar that, although critical for maintaining structural integrity, irreversibly impairs contractile function [25].”
InfluentialCui, Y., Wang, Y., Wang, S., Du, B., Li, X., & Li, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186033 · Cited by 29
“However, identification of this detrimental fibrosis remains challenging and deserves more investigation on early detection, precise stratification, and prediction of the evolution of left ventricular (LV) function of cardiovascular diseases [4].”
BackgroundSenesi, G., Lodrini, A. M., Mohammed, S., Mosole, S., Hjortnaes, J., Veltrop, R. J. A., Kubat, B., Ceresa, D., Bolis, S., Raimondi, A., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae243 · Cited by 29
Camargo, R. O., Abual’anaz, B. M., Rattan, S. G., Filomeno, K. L., & Dixon, I. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12947 · Cited by 30
“It is well known that cardiac fibrosis is driven, in part, by TGFβ1/ Smad signalling, in resident cardiac fibroblasts(34) however cardiac fibrosis per se has no druggable targets for translatable cures.(6) Most current lines of investigation are focused on endogenous fibrotic mechanisms, while those focused on anti-fi…”
BackgroundGebauer, A. M., Pfaller, M. R., Braeu, F. A., Cyron, C. J., & Wall, W. A. (2023) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-023-01747-w · Cited by 30
“In the severe hypertensive case, our model predicts only a partial reversal of fibrosis which is in line with studies on patients after treatment of advanced hypertension (Frangogiannis 2020).”
ResultMyocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis
Liu, D., Wang, M., Murthy, V., McNamara, D. M., Nguyen, T. T. L., Philips, T. J., Vyas, H., Gao, H., Sahni, J., Starling, R. C., et al. (2023) · Circulation Research · doi:10.1161/circresaha.123.323200 · Cited by 30
Tian, G., Zhou, J., Quan, Y., Kong, Q., Li, J., Xin, Y., Wu, W., Tang, X., & Liu, X. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102907 · Cited by 29
Multi-omics strategies to decode the molecular landscape of cellular senescence
Basilicata, M. G., Sommella, E., Scisciola, L., Tortorella, G., Malavolta, M., Giordani, C., Barbieri, M., Campiglia, P., & Paolisso, G. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102824 · Cited by 31
Targeting Inflammation and Fibrosis in Cardiovascular Disease: Emerging Mechanisms and Therapies
Cabrera-Fuentes, H. A., Barreto, G., Pérez‐Campos, E., Nivon‐Torres, G. F., González, A. A. G., Al-Suhaimi, E. A., & Liehn, E. A. (2025) · The FASEB Journal · doi:10.1096/fj.202500970r · Cited by 30
The role of immunosuppressive myofibroblasts in the aging process and age-related diseases
Salminen, A. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02360-1 · Cited by 28
Genetic Factors Altering Immune Responses in Atrial Fibrillation
Ninni, S., Dombrowicz, D., de Winther, M. P. J., Staels, B., Montaigne, D., & Nattel, S. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.034 · Cited by 28
Basu, C., Cannon, P. L., Awgulewitsch, C. P., Galindo, C. L., Gamazon, E. R., & Hatzopoulos, A. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-59155-8 · Cited by 28
Piezo1:the potential new therapeutic target for fibrotic diseases
Liu, X. Z., Niu, W., Zhao, S., Zhang, W., Ying, Z., & Li, J. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.09.001 · Cited by 29
Insights into the post-translational modifications in heart failure
Zhang, X., Wang, Y., Li, H., Wang, D. W., & Chen, C. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102467 · Cited by 28
The role of IL-17 family cytokines in cardiac fibrosis
Huang, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1470362 · Cited by 27
The Role of HECT-Type E3 Ligase in the Development of Cardiac Disease
Goto, J., Otaki, Y., Watanabe, T., & Watanabe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116065 · Cited by 27
Recent Advances in Microbiota-Associated Metabolites in Heart Failure
Masenga, S. K., Povia, J. P., Lwiindi, P. C., & Kirabo, A. (2023) · Biomedicines · doi:10.3390/biomedicines11082313 · Cited by 28
Understanding aconite's anti-fibrotic effects in cardiac fibrosis
Xing, Z., Yang, C., Feng, Y., He, J., Peng, C. Y., & Li, D. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155112 · Cited by 27
Wang, X., Chen, X., Wang, Y., He, X., Li, L., Wang, X., Huang, Y., Fan, G., & Ni, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1467132 · Cited by 30
Therapeutic Spp1 silencing in TREM2+ cardiac macrophages suppresses atrial fibrillation
Momin, N., Pabel, S., Rudra, A., Kumowski, N., Lee, I., Seung, H., Mentkowski, K. I., Bapat, A. C., Yamazoe, M., Stengel, L., et al. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00806-6 · Cited by 29
Zhao, K., Zhang, J., Xu, T., Yang, C., Weng, L., Wu, T., Wu, X., Miao, J., Guo, X., Tu, J., et al. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100130 · Cited by 26
“…via a caveolin-1-dependent pathway Since the inflammatory response has been shown to be vital in the progression of cardiac remodeling (Hanna and Frangogiannis, 2020), we next investigated the mRNA expression of several proinflammatory cytokines, including TNF-α, IL-1β, and IL-6, in cardiac…”
BackgroundHameed, S., Pan, K., Su, W., Trupp, M., Mi, L., & Zhao, J. (2022) · Particle and Fibre Toxicology · doi:10.1186/s12989-022-00493-8 · Cited by 26
“Macrophages are found at the site of fibrosis, that activate reparative and maladaptive processes that lead to organ dysfunction in many different diseases [36, 37].”
BackgroundLiu, M., Peng, T., Hu, L., Wang, M., Guo, D. S., Qi, B., Ren, G., Wang, D., Li, Y., Song, L., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.77469 · Cited by 26
Rypdal, K. B., Melleby, A. O., Robinson, E. L., Li, J., Palmero, S., Seifert, D. E., Martin, D., Clark, C., López, B., Andreassen, K. E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04361-1 · Cited by 28
Yu, W., Jiang, Y., Xu, H., & Zhou, Y. (2023) · Biomedicines · doi:10.3390/biomedicines11020442 · Cited by 27
COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations
Shu, H., Zheng, W., Li, N., Zhang, Z., Ceesay, B. M., Peng, Y., Zhou, N., & Wang, D. W. (2023) · Aging and Disease · doi:10.14336/ad.2023.0314 · Cited by 29
Zhang, J., Cao, J., Qian, J., Gu, X., Zhang, W., & Chen, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115380 · Cited by 28
Visone, R., Paoletti, C., Cordiale, A., Nicoletti, L., Divieto, C., Rasponi, M., Chiono, V., & Occhetta, P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301481 · Cited by 27
Modulation of anti-cardiac fibrosis immune responses by changing M2 macrophages into M1 macrophages
Chen, S., Wang, K., Fan, Z., Zhou, T., Li, R., Zhang, B., Chen, J., Chi, J., Wei, K., Liu, J., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00858-z · Cited by 26
Shi, L., Deng, J., He, J., Zhu, F., Jin, Y., Zhang, X., Ren, Y., & Du, X. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176632 · Cited by 25
Peng, R., Shi, J.-J., Jiang, M., Qian, D., Yan, Y., Bai, H., Yu, M., Cao, X., Fu, S., & Lu, S.-F. (2024) · Mediators of Inflammation · doi:10.1155/2024/8237681 · Cited by 25
Zhang, Z.-W., Wang, Y., Chen, X., Wu, C., Zhou, J., Chen, Y., Liu, X., & Tang, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102542 · Cited by 25
Thor: a platform for cell-level investigation of spatial transcriptomics and histology
Zhang, P., Chen, W., Tran, T. H., Zhou, M., Carter, K. N., Kandel, I., Li, S., Hoi, X. P., Sun, Y., Lai, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62593-1 · Cited by 32
Kostecki, G., Shi, Y., Chen, C. S., Reich, D. H., Entcheva, E. G., & Tung, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-83398-4 · Cited by 25
Banks, T., Rajapaksha, M., Zhang, L., Bai, F., Wang, N.-P., & Zhao, Z. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175048 · Cited by 26
Lu, Z., Hao, C., Qian, H., Zhao, Y., Bo, X., Yao, Y., Ma, G., & Chen, L. (2022) · iScience · doi:10.1016/j.isci.2022.104780 · Cited by 25
Schumacher, D., Curaj, A., Staudt, M., Simsekyilmaz, S., Kanzler, I., Boor, P., Klinkhammer, B. M., Li, X., Bucur, O., Kaabi, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314571 · Cited by 28
Pang, P., Si, W., Wu, H., Wang, C., Liu, K., Jia, Y., Zhang, Z., Zhang, F., Kong, X., Yang, Y., et al. (2023) · Translational research · doi:10.1016/j.trsl.2023.01.008 · Cited by 29
Tissue Sodium Accumulation Induces Organ Inflammation and Injury in Chronic Kidney Disease
Ito, Y., Sun, T., Tanaka, H., Yamaguchi, M., Kinashi, H., Sakata, F., Kunoki, S., Sakai, Y., & Ishimoto, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098329 · Cited by 29
“Generally, myocardial fibrosis is often initiated by the injury or death of cardiomyocytes, which results in increased extracellular matrix production by cardiac fibroblasts and myofibroblasts to repair the damaged tissues [82,83].”
BackgroundThe Molecular Role of Immune Cells in Dilated Cardiomyopathy
Wang, E., Zhou, R., Li, T., Hua, Y., Zhou, K., Li, Y., Luo, S., & An, Q. (2023) · Medicina · doi:10.3390/medicina59071246 · Cited by 28
“These immune cells secrete a variety of fibrosis mediators, such as cytokines, growth factors, and matricellular proteins, which play a role in the development and progression of myocardial fibrosis [51,52].”
BackgroundThe role of periostin in cardiac fibrosis
Qiao, B., Liu, X., Wang, B., & Wei, S. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10361-y · Cited by 27
“The abnormal and uncontrolled fibrotic remodeling reflects the limited regenerative ability of the myocardium and inappropriate repair programs [4].”
MicroRNAs regulating signaling pathways in cardiac fibrosis: potential role of the exercise training
Caria, A. C. I., Rodrigues, L. F., Joaquim, V. H. A., Sousa, R. A. L. D., Fernandes, T. M., & de Oliveira, E. M. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00410.2023 · Cited by 25
Mechanotransductive receptor Piezo1 as a promising target in the treatment of fibrosis diseases
Xu, Y., Huang, Y., Cheng, X., Hu, B., Jiang, D., Wu, L., Peng, S., & Hu, J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1270979 · Cited by 24
“This impairs cardiac compliance and diastolic function (Frangogiannis, 2021; Liu M. et al., 2021; Kurose, 2021; Shao et al., 2022).”
BackgroundSeropian, I. M., El-Diasty, M. M., Sherbini, A. E., Gonzalez, G. E., & Rabinovich, G. A. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.10.002 · Cited by 24
Atrial fibrosis in atrial fibrillation: Mechanisms, mapping techniques and clinical applications
Horrach, C. V., Bevis, L., Nwanna, C., Zolotarev, A. M., Ehnesh, M., Misghina, S. B., Al‐Aidarous, S., Honarbakhsh, S., & Roney, C. H. (2025) · The Journal of Physiology · doi:10.1113/jp288680 · Cited by 24
Mota, K. O., de Vasconcelos, C. M. L., Kirshenbaum, L. A., & Dhalla, N. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157311 · Cited by 26
“There is also evidence to suggest that AGE deposition in cardiovascular tissues correlates with disease progression in conditions like diabetes mellitus, hypertension, and heart failure [59,60].”
Bastos, V. A. F., de Souza, A. G., Guedes, V. C. S., & Cunha, T. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199476 · Cited by 27
“Myofibroblasts derive primarily from resident fibroblasts through fibroblast-myofibroblast transition (FMT); however, endothelial-to-mesenchymal transition (EndoMT) and activation of epicardial cells or MSC-like populations also contribute [112–114].”
Non-coding RNA and arrhythmias: expression, function, and molecular mechanism
Zeng, Y., Wu, N., Zhang, Z., Zhong, L., Li, G., & Li, Y. (2023) · EP Europace · doi:10.1093/europace/euad047 · Cited by 25
Parichatikanond, W., Duangrat, R., & Mangmool, S. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175780 · Cited by 25
Cardiac resident macrophages: key regulatory mediators in the aftermath of myocardial infarction
Chen, C., Wang, J., Liu, C., & Hu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207100 · Cited by 25
“Myocardial fibrosis is the expansion of the myocardial interstitium resulting from the net accumulation of extracellular matrix (ECM) proteins and is a critical pathophysiological factor that affects ventricular remodeling after MI (46).”
BackgroundInfluentialImmunometabolism in the Aging Heart
Mapuskar, K. A., London, B., Zacharias, Z. R., Houtman, J. C. D., & Allen, B. G. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.039216 · Cited by 26
“94,95 Age-associated pathologies are often associated with changes in the different subsets of myeloid cell populations and immunosenescence.”
Yeo, T. M., Chin, C. W. L., Seah, A. C. W., Cheng, L. J., Lin, W., Dalakoti, M., Foo, R., & Wang, W. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf083 · Cited by 23
Circulating Non-Coding RNAs as Indicators of Fibrosis and Heart Failure Severity
Boichenko, V., Noakes, V. M., Reilly-O’Donnell, B., Luciani, G. B., Emanueli, C., Martelli, F., & Gorelik, J. (2025) · Cells · doi:10.3390/cells14070553 · Cited by 24
“As regulatory biological molecules, ncRNAs largely control gene and protein expression, and thus have the potential to alter the pathophysiology and prognosis of cardiac conditions like HF [31].”
The theatrics of collagens in the myocardium: the supreme architect of the fibrotic heart
Chakraborty, S., Dutta, A., Roy, A., Joshi, A., & Basak, T. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.01043.2024 · Cited by 24
Macrophage-Derived CCL24 Promotes Cardiac Fibrosis Via Fibroblast CCR3
Parthiban, P., Barrow, F., Wang, H., Chalise, U., Araujo, N., Souza-Neto, F., Nguyen, H., Draxler, M., Pallais, J. P., Yücel, D., et al. (2025) · Circulation Research · doi:10.1161/circresaha.125.326599 · Cited by 23
Tachycardiomyopathy entails a dysfunctional pattern of interrelated mitochondrial functions
Paulus, M. G., Renner, K., Nickel, A. G., Brochhausen, C., Limm, K., Zügner, E., Baier, M. J., Pabel, S., Wallner, S., Birner, C. M., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00949-0 · Cited by 24
Xu, H., Miao, H., Chen, G., Zhang, G., Hua, Y., Wu, Y., Xu, T., Han, X., Hu, C., Pang, M., et al. (2023) · Journal of Ginseng Research · doi:10.1016/j.jgr.2023.06.007 · Cited by 24
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure
van den Berg, P. F., Aboumsallem, J. P., Screever, E. M., Shi, C., de Wit, S., Bračun, V., Yousif, L. I. E., Geerlings, L., Wang, D., Ho, J. E., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.03.015 · Cited by 24
“In HF, fibrosis predominantly results from either direct cardiac injury during a myocardial infarction or increased ventricular remodeling caused by perturbations in hemodynamic workload.(36) Consequently, collagen deposition in the ECM increases and cardiac stiffening ensues, causing a detrimental decline in cardiac…”
BackgroundTherapeutic application of adipose-derived stromal vascular fraction in myocardial infarction
Фанилевич, Г. И., Beylerli, O., Ilyasova, T., Ahmad, A., Shi, H., & Chekhonin, V. P. (2024) · iScience · doi:10.1016/j.isci.2024.109791 · Cited by 23
CVD and COVID-19: Emerging Roles of Cardiac Fibroblasts and Myofibroblasts
Katwa, L. C., Mendoza, C., & Clements, M. (2022) · Cells · doi:10.3390/cells11081316 · Cited by 24
“Fibroblasts are activated by Ang II, TGF-β, and cytokines [9,11], all of which are upregulated during SARS-CoV-2 infection [5,27,46].”
BackgroundMulticellular 3D Models for the Study of Cardiac Fibrosis
Picchio, V., Floris, E., Derevyanchuk, Y., Cozzolino, C., Messina, E., Pagano, F., Chimenti, I., & Gaetani, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911642 · Cited by 23
“It represents the bottleneck of several pathological processes, including ischemic/non-ischemic cardiomyopathy, metabolic syndrome, diabetes, and aging [1].”
BackgroundCauses, Diagnosis, Treatment, and Prognosis of Cardiac Fibrosis: A Systematic Review
BaniHani, H. A., Khaled, L. H. I., Sharaa, N. M. A., Saleh, R. A. A., Ghalaita, A. K. B., Sulaiman, A. S. B., & Holeihel, A. (2025) · Cureus · doi:10.7759/cureus.81264 · Cited by 22
Poddi, S., Lefter, C. L., Linardi, D., Ardigò, A., Luciani, G. B., & Rungatscher, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12050192 · Cited by 22
“Replacement fibrosis is predominantly associated with systolic dysfunction; interstitial and perivascular fibrosis typically reduce left ventricular compliance and then alter diastolic function, with less pronounced or late effects on systolic function [3].”
Cardiac fibrosis in oncologic therapies
Packard, R. R. S. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100575 · Cited by 23
Jones, C. A., Wallace, M. J., Bandaru, P., Woodbury, E. D., Mohler, P. J., & Wold, L. E. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad113 · Cited by 23
MicroRNA in Fibrotic Disorders: A Potential Target for Future Therapeutics
Mehjabin, A., Kabir, M., Micolucci, L., Akhtar, M. M., Mollah, A. K. M. M., & Islam, M. S. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2811317 · Cited by 22
SnoRNAs in cardiovascular development, function, and disease
Chabronova, A., Holmes, T. L., Hoang, D. M., Denning, C. N., James, V. H., Smith, J. G. W., & Peffers, M. J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.004 · Cited by 23
Yang, B., Wang, Z., Niu, K., Li, T., Tong, T., Li, S., Su, L., Wang, Y., Shen, C., Jin, X., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01826-0 · Cited by 22
“Cardiac remodeling refers to the structural and functional changes that occur in the heart in response to various physiological or pathological stimuli [1].”
BackgroundInfluentialBuja, L. M. (2024) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2024.104944 · Cited by 24
SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis
Lin, H., Guan, L., Meng, L., Uzui, H., & Guo, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700366 · Cited by 22
“CFs switched from a resting type to an activated type increasing their proliferation and migration capacity and began to secrete large amounts of extracellular matrix, causing fibrosis of the heart (Frangogiannis, 2021).”
BackgroundNiro, F., Fernandes, S., Cassani, M., Apostolico, M., Cruz, J. O. L., Pereira-Sousa, D., Pagliari, S., Vinarský, V., Zdráhal, Z., Potěšil, D., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.07.003 · Cited by 22
Status and role of the ubiquitin–proteasome system in renal fibrosis
Chen, Y., Dai, R., Cheng, M., Wang, W., Liu, C., Cao, Z., Ge, Y., Wang, Y., & Zhang, L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117210 · Cited by 21
Aging at the Crossroads of Organ Interactions: Implications for the Heart
Sen, I., Trzaskalski, N. A., Hsiao, Y., Liu, P. P., Shimizu, I., & Dérumeaux, G. (2025) · Circulation Research · doi:10.1161/circresaha.125.325637 · Cited by 23
“32 35 In the elderly, the vasculature undergoes various changes such as endothelial dysfunction with impaired endothelium-dependent vasodilation, progressive vascular calcification, alterations in the elastin-collagen balance, and accumulation of advanced glycation end products, all contributing to…”
Hong, S. B., Jeong, J.-O., & Choi, H. (2025) · Gels · doi:10.3390/gels11070564 · Cited by 24
“Prolonged or excessive inflammation after ischemic injury can impair matrix remodeling and functional recovery [119].”
Wang, J., Bennett, D. S. Y., Echard, E. J., Chen, B., Ciampa, G., Zhao, W., Shi, Q., Yoon, J., Weiss, R. M., Grueter, C. E., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.073937 · Cited by 21
Cozzolino, C., Floris, E., Icolaro, F., Pontecorvi, V., Bordin, A., Frati, G., Pagano, F., FALCO, E. D., Picchio, V., & Chimenti, I. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107970 · Cited by 24
He, Z., An, Q., Wei, B., Zhou, W., Wei, B., Gong, Y., Zhang, X., Gao, G., Dong, G., Huo, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01207 · Cited by 22
The heart under pressure: immune cells in fibrotic remodeling
Theall, B. P., & Alcaide, P. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100484 · Cited by 21
Jong, J., Pinney, J. R., & Packard, R. R. S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.919719 · Cited by 24
“Myocardial fibrosis (114) may occur as a result of AIC.”
BackgroundQi, R., Lin, E., Song, J., Wang, Y., & Lin, L. (2022) · Molecules · doi:10.3390/molecules27248784 · Cited by 22
“replacement fibrosis, interstitial fibrosis and perivascular fibrosis (Figure 1) [7,8].”
BackgroundPiepho, A. B., Lowe, J., Cumby, L. R., Dorn, L. E., Lake, D. M., Rastogi, N., Gertzen, M. D., Sturgill, S. L., Odom, G. L., Ziolo, M. T., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.001 · Cited by 21
The Versatility of Collagen in Pharmacology: Targeting Collagen, Targeting with Collagen
Revert‐Ros, F., Ventura, I., Prieto-Ruiz, J. Á., Hernández‐Andreu, J. M., & Revert, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126523 · Cited by 24
“In contrast, dilated cardiomyopathy, which could be the end stage of hypertensive heart disease, induces diffuse fibrosis throughout the muscle tissue [26].”
BackgroundYang, H. Y., Li, J., Shen, H., Jia, D., Jia, Y., Wang, Z., Yu, Q., Shen, Z., & Zhang, Y. (2024) · Journal of Material Science and Technology · doi:10.1016/j.jmst.2024.07.028 · Cited by 23
Li, Y., & Xu, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106049 · Cited by 21
Galectin-3 Inhibition Ameliorates Streptozotocin-Induced Diabetic Cardiomyopathy in Mice
Zhu, N., Zhu, L., Huang, B., Xiang, W., & Zhao, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.868372 · Cited by 23
Yang, Y., Shao, M., Cheng, W., Yao, J., Ma, L., Wang, Y., & Wang, W. (2023) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2023/3801908 · Cited by 23
“As the vital regulator in the development of cardiac fibrosis, TGF-β1 displays a crucial function in enhancing extracellular matrix (ECM) deposition [143, 144].”
BackgroundRetractedZhang, Y., Wu, Y., Li, M., Mijiti, A., & Cheng, L.-F. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05624-7 · Cited by 20
“Numerous studies have linked DCM, ICM, and MI to MF [2], heightening HF risk.”
BackgroundThe immunology of diabetic cardiomyopathy
Song, M., Dai, H., Zhou, Q., & Meng, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1542208 · Cited by 22
Ye, Z., Wang, S., Wan, Z., Huang, B., & Guo, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610429 · Cited by 20
“However, the stiff nature of collagen tissue reduces the heart ’ s contractility and fl exibility, impairing cardiac function (Frangogiannis, 2021).”
Kim, J., Zhang, X., Wang, R., Najer, A., Lau, Q. Y., Cammack-Najera, A., Kim, J. A., Kang, Y. K., Xie, R., Kim, H., et al. (2025) · Advanced Materials · doi:10.1002/adma.202418909 · Cited by 20
Hippo-Yap signaling in cardiac and fibrotic remodeling
Re, D. P. D. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100492 · Cited by 22
Moita, M. R., Silva, M. M., Diniz, C., Serra, M., Hoet, R., Barbas, A., & Simão, D. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1015473 · Cited by 23
“STRING analysis showed an interconnection of a large group of proteins (19 in total), from those three proteins were not previously linked to fibrotic conditions: (1) mannose receptor C type 2 (MRC2) that acts also as a collagen receptor was identified as an interacting partner of PLAUR; (2) latent transforming growth…”
BackgroundSuppression of SMOC2 alleviates myocardial fibrosis via the ILK/p38 pathway
Rui, H., Zhao, F., Yuhua, L., & Hong, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.951704 · Cited by 20
“However, fibrosis of the myocardium is a complex pathological process with a multifactorial etiology, and further investigation into the specific in-depth molecular mechanisms is still imperative for improving prognoses (4, 7).”
BackgroundRuocco, G., Zoso, A., Mortati, L., Carmagnola, I., & Chiono, V. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00483 · Cited by 20
Chu, L., Xie, D., & Xu, D. (2023) · Biomolecules · doi:10.3390/biom13091382 · Cited by 20
“Transforming growth factor is synthesized and released via cardiomyocytes in response to mechanical stretch, thereby activating fibroblasts [178,179].”
BackgroundGonzalo, A., Augustin, C. M., Bifulco, S., Telle, Å., Chahine, Y., Kassar, A., Guerrero‐Hurtado, M., Durán, E., Martínez‐Legazpi, P., Flores, Ó., et al. (2024) · The Journal of Physiology · doi:10.1113/jp287011 · Cited by 20
Metadata
- Authors
- Frangogiannis, N. G.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Frangogiannis, Nikolaos G
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-02
- Volume
- 117
- Issue
- 6
- Pages
- 1450-1488
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- PMC
- PMC8152700
- OpenAlex
- W4210607007
- Cited by
- 1,229
- References
- 615
- Citations by year
- 2026: 265 · 2025: 319 · 2024: 273 · 2023: 210 · 2022: 130 · 2021: 32
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Cardiovascular Research (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 HL76246, R01 HL85440, R01 HL149407)
- U.S. Department of Defense (PR151134, PR151029, PR181464)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- myocardial fibrosis, myocardial fibroblasts, myofibroblasts, extracellular matrix deposition, TGF-beta, platelet-derived growth factor, cytokines, mechanoreceptors, integrins, pressure overload, myocardial infarction, heart failure, familial cardiomyopathy, diabetic cardiomyopathy, cardiac arrhythmias
- MeSH terms
- Antifibrotic Agents, Animals, Extracellular Matrix, Fibroblasts, Fibrosis, Humans, Cardiomyopathies, Myocytes, Cardiac, Mechanotransduction, Cellular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.